Novel therapeutics in metastatic bladder cancer

Expert Opinion on Investigational Drugs

Volumn 17, Issue 12, 2008, Pages 1889-1899

  Lekas, Alexandros ^a   Papathomas, Thomas G ^b   Papatsoris, Athanasios G ^c   Deliveliotis, Charalambos ^a   Lazaris, Andreas C ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

Chemotherapy; Metastatic urothelial carcinoma; Novel biological agents

Indexed keywords

AXITINIB; BEVACIZUMAB; BORTEZOMIB; BS 247550; CARBOPLATIN; CETUXIMAB; CISPLATIN; DEFOROLIMUS; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IXABEPILONE; LAPATINIB; LAROTAXEL; LONAFARNIB; METHOTREXATE; MOLECULAR MARKER; OXALIPLATIN; PACLITAXEL; PEMETREXED; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINFLUNINE; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ADD ON THERAPY; BLADDER CANCER; BLADDER METASTASIS; BLADDER TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; HUMAN; KIDNEY DYSFUNCTION; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; PREDICTION; REVIEW; TREATMENT RESPONSE; ANIMAL; GENETICS; METABOLISM; METASTASIS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM METASTASIS; PLATINUM COMPOUNDS; URINARY BLADDER NEOPLASMS;

EID: 58149375901     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802514195     Document Type: Review

References (120)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;8:71-96
2. Papatsoris AG, Kachrilas S, Gekas A. Where are we with the treatment of metastatic bladder cancer? Expert Opin Investig Drugs 2007;6:1311-1314
3. Chee KG, Cambio A, Lara PN Jr. Recent developments in advanced urothelial cancer. Curr Opin Urol 2005;5:342-349 (Pubitemid 41242256)
4. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J Clin Oncol 2000;8:3068-3077 (Pubitemid 30677086)
5. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;3:4602-4608 (Pubitemid 46224062)
6. Roberts JT, von der Maase H, Sengeløv L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 2006;7(Suppl.5):v118-22 (Pubitemid 43985220)
7. Lehmann J, Retz M, Steiner G, et al. Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the Phase III study of chemotherapy of advanced urothelial carcinoma in Germany. Urologe A 2003;2:1074-1086
8. Ochi T, Ozawa A, Tanji N, et al. Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin). Nippon Hinyokika Gakkai Zasshi 2006;97(6):777-781 (Pubitemid 44622577)
9. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007;9(Suppl.1):62-79 (Pubitemid 46186484)
10. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005;174:14-20 (Pubitemid 40825662)
11. Garcia JA, Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 2006;4:5545-5551 (Pubitemid 46631335)
12. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;9:2638-2646 (Pubitemid 32441368)
13. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC Phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;2:50-54 (Pubitemid 41814532)
14. Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, Phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004;2:220-228 (Pubitemid 41095085)
15. Lin CC, Hsu CH, Huang CY, et al. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity. Cancer 2006;106:1269-1275 (Pubitemid 43363903)
16. Lin CC, Hsu CH, Huang CY, et al. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma. J Urol 2007;77:84-89 (Pubitemid 44879476)
17. Bellmunt J, Albiol S, Suárez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 2008 [Epub ahead of print]
18. Galsky MD. The role of taxanes in the management of bladder cancer. Oncologist 2005;10:792-798 (Pubitemid 43152696)
19. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-3181 (Pubitemid 29470648)
20. Bellmunt J, Albanell J, Paz-Ares L, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a Phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002;95:751-757 (Pubitemid 34839666)
21. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004;100:1639-1645
22. Dogliotti L, Cartenì G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007;52:134-141 (Pubitemid 46803003)
23. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 2004;64:479-484 (Pubitemid 39200741)
24. Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 2006;106:297-303
25. Nogué-Aliguer M, Carles J, Arrivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003;97:2180-2186 (Pubitemid 36444058)
26. Bellmunt J, de Wit R, Albanell J, et al. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 2001;37:2212-2215
27. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:2527-2533 (Pubitemid 32391224)
28. Hainsworth JD, Meluch AA, Litchy S, et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 2005;103:2298-2303
29. Johannsen M, Sachs M, Roigas J, et al. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. Eur Urol 2005;48:246-251 (Pubitemid 40957098)
30. Edelman MJ, Meyers FJ, Miller TR, et al. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology 2000;55:1-525 (Pubitemid 30157956)
31. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997;80:1966-1972 (Pubitemid 27479792)
32. Powles T, Perry J, Shamash J, et al. A comparison of the platinum analogues in bladder cancer cell lines. Urol Int 2007;79:67-72 (Pubitemid 47051822)
33. Carles J, Esteban E, Climent M, et al. Gemcitabine and oxaliplatin combination: a multicenter Phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol 2007;18:1359-1362 (Pubitemid 47305010)
34. Theodore C, Bidault F, Bouvet-Forteau N, et al. A Phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 2006;17:990-994 (Pubitemid 43778992)
35. Sternberg CN, Calabro F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92:2993-2998 (Pubitemid 33136193)
36. Meluch AA, Greco FA, Burris HA III, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19:3018-3024 (Pubitemid 32565438)
37. Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group study. J Clin Oncol 2005;23:1185-1191 (Pubitemid 46202275)
38. Srinivas S, Guardino AE. A nonplatinum combination in metastatic transitional cell carcinoma. Am J Clin Oncol 2005;238:114-118 (Pubitemid 40503431)
39. Takahashi T, Higashi S, Nishiyama H, et al. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Jpn J Clin Oncol 2006;36:104-108
40. Kaufman DS, Carducci MA, Kuzel TM, et al. A multi-institutional Phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 2004;22:393-397 (Pubitemid 40500816)
41. Ardavanis A, Tryfonopoulos D, Alexopoulos A, et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a Phase II study. Br J Cancer 2005;92:645-650 (Pubitemid 40460598)
42. Gitlitz BJ, Baker C, Chapman Y, et al. A Phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 2003;98:1863-1869 (Pubitemid 37310229)
43. Dreicer R, Manola J, Schneider DJ, et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2003;97:2743-2747 (Pubitemid 36605141)
44. Dumez H, Martens M, Selleslach J, et al. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a Phase II and pharmacologic study. Anticancer Drugs 2007;18:211-218 (Pubitemid 44967431)
45. Lara PN Jr, Meyers FJ, Law LY, et al. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Cancer 2004;100:82-88
46. Dreicer R, Li S, Manola J, et al. Phase 2 trial of epothilone B. analog. BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 2007;110:759-763
47. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24:3451-3457 (Pubitemid 46638903)
48. Galsky MD, Mironov S, Iasonos A, et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007;25:265-270 (Pubitemid 46774696)
49. von der Maase H, Lehmann J, Gravis G, et al. A Phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 2006;17:1533-1538 (Pubitemid 44542040)
50. Culine S, Theodore C, De Santis M, et al. A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006;94:1395-1401 (Pubitemid 43772272)
51. Bellmunt J, von der Maase H, Theodore C, et al. Randomised Phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU) [abstract 5028]. J Clin Oncol 2008 26(May 20 Suppl)
52. Sonpavde G, Ross R, Powles T, et al. Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int 2008;101:937-943 • An updated mini-review of novel chemotherapeutic and biologic agents for bladder cancer.
53. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004
54. Small EJ, Halabi S, Dalbagni G, et al. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer 2003;97:2090-2098 (Pubitemid 36401559)
55. Kramer C, Klasmeyer K, Bojar H, et al. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer 2007;109:2016-2024 (Pubitemid 46744196)
56. Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994;101:166-176 (Pubitemid 24061443)
57. Popov Z, Gil-Diez-De-Medina S, Ravery V, et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004;22:93-101 (Pubitemid 38479801)
58. Bue P, Wester K, Sjöström A, et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 1998;76:189-193 (Pubitemid 28180371)
59. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6:4874-4884 (Pubitemid 32110432)
60. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-265 (Pubitemid 29085177)
61. Black PC, Brown GA, Inamoto T, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008;14:1478-1486
62. Jacobs MA, Wotkowicz C, Baumgart ED, et al. Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib. J Urol 2007;178:1510-1514 (Pubitemid 47368378)
63. Yang JL, Qu XJ, Hayes VM, et al. Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. BJU Int 2007;99:1539-1545 (Pubitemid 47164800)
64. Jin Y, Iwata KK, Belldegrun A, et al. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther 2006;5:1754-1763 (Pubitemid 44323243)
65. McHugh LA, Kriajevska M, Mellon JK, Griffiths TR. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens-evidence of schedule-dependent synergy. Urology 2007;69:390-394 (Pubitemid 46274953)
66. Machiels JP, Wulfing C, Richel DJ, et al. A single arm, multicenter, open-label Phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract. Interim analysis [abstract 4615]. Proc Am Soc Clin Oncol 2004;22
67. Philips GK, Halabi S, Sanford BL, et al. A Phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 2008;101:20-25 (Pubitemid 350233568)
68. Jimenez RE, Hussain M, Bianco FJ. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440-2447 (Pubitemid 32751647)
69. Latif Z, Watters AD, Dunn I, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004;40:56-63
70. Yamada Y, Naruse K, Nakamura K, et al. Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization. Oncol Rep 2007;18:1183-1187
71. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter Phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218-2224 (Pubitemid 46954646)
72. Simon R, Atefy R, Wagner U, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 2003;107:764-772 (Pubitemid 37339730)
73. Jarvinen TA, Liu ET. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 2006;6:579-602 (Pubitemid 44691001)
74. Theodoropoulos VE, Lazaris ACh, Sofras F, et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004;46:200-208 (Pubitemid 38902737)
75. Xia G, Kumar SR, Hawes D, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006;175:1245-1252 (Pubitemid 43312956)
76. Suzuki K, Morita T, Tokue A. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol 2005;12:152-158 (Pubitemid 40459945)
77. Yang CC, Chu KC, Yeh WM. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004;22:1-6 (Pubitemid 38542704)
78. Inoue K, Chikazawa M, Fukata S, et al. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 2002;8:2389-2398 (Pubitemid 34753614)
79. Inoue K, Chikazawa M, Fukata S, et al. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 2003;9:886-899 (Pubitemid 36182629)
80. Muramaki M, Miyake H, Hara I, et al. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model. J Urol 2004;172:1485-1489 (Pubitemid 39249754)
81. Du Z, Hou S. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol 2003;170:2000-2003 (Pubitemid 37254996)
82. Kikuchi E, Menendez S, Ohori M, et al. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin Cancer Res 2004;10:1835-1842 (Pubitemid 38435575)
83. Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis - translation from murine model to clinical trial. Cancer Metastasis Rev 2007;26:623-634 (Pubitemid 350115114)
84. Bellmunt J, Maroto P, Mellado B, et al. Phase II study of sunitinib as first l ine treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy [abstract 291]. Proc Am Soc Clin Oncol 2008
85. Gallagher DJ, Milowsky MI, Gerst SR, et al. Final results of a Phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma [abstract 5082]. J Clin Oncol 2008;26(May 20 Suppl)
86. Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008;9:658-671 (Pubitemid 351777169)
87. Zhu K, Pino MS, Siefker-Radtke AO, et al. AG-013736, a novel VEGF receptor and PDGF receptor inhibitor with potent activity against human bladder carcinoma in vitro and in vivo [abstract 13109]. J Clin Oncol 2006;24(June 20 Suppl)
88. Lopez-Beltran A, Maclennan GT, de la Haba-Rodriguez J, et al. Research advances in apoptosis-mediated cancer therapy: a review. Anal Quant Cytol Histol 2007;29:71-78 (Pubitemid 46649484)
89. Bellmunt J, de Wit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol 2003;47:195-206 (Pubitemid 36945316)
90. Cho HJ, Kim JK, Kim KD, et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 2006;237:56-66
91. Miyake H, Hara I, Yamanaka K, et al. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. J Urol 1999;162:2176-2181 (Pubitemid 29436917)
92. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol 2002;3:672-683 (Pubitemid 35314910)
93. Glackin AJ, Gray SB, Johnston SR, et al. Antisense oligonucleotides in the treatment of bladder cancer. Expert Opin Biol Ther 2005;5:67-77 (Pubitemid 40116480)
94. Schaaf A, Sagi S, Langbein S, et al. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 2004;22:188-192 (Pubitemid 38950623)
95. Bilim V, Kasahara T, Noboru H, et al. Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and adriamycin on transitional cell cancer cells. Cancer Lett 2000;31;155:191-198 (Pubitemid 30259134)
96. Duggan BJ, Maxwell P, Kelly JD, et al. The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol 2001;166:1098-1105 (Pubitemid 32751052)
97. Bolenz C, Becker A, Trojan L, et al. Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides. Urol Oncol 2007;25:476-482 (Pubitemid 350151900)
98. Gee J, Lee IL, Jendiroba D, et al. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 2006;15:471-477
99. Mohammed SI, Dhawan D, Abraham S, et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 2006;5:329-336
100. Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008;7:1347-1354 •• A very interesting review of mammalian target of rapamycin (mTOR) inhibitors as novel anticancer therapeutics of urologic malignancies.
101. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol 2003;170:1987-1993 (Pubitemid 37254994)
102. Winquist E, Moore MJ, Chi KN, et al. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005;23:143-149 (Pubitemid 40720377)
103. Theodore C, Geoffrois L, Vermorken JB, et al. Multicentre EORTC study 16997: feasibility and Phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005;41:1150-1157 (Pubitemid 40725573)
104. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-137 (Pubitemid 32095710)
105. Rosenberg JE, von der Maase H, Seigne JD, et al. A Phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 2005;103:2035-2041 (Pubitemid 40605110)
106. Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004;3:279-290 (Pubitemid 39193703)
107. Lashinger LM, Zhu K, Williams SA, et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005;65:4902-4908 (Pubitemid 40740830)
108. Papageorgiou A, Kamat A, Benedict WF, et al. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006;5:3032-3041 (Pubitemid 46092044)
109. Rosenberg JE, Halabi S, Sanford BL, et al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol 2008;19:946-950 (Pubitemid 351627312)
110. Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, Papavassiliou AG. Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol 2008;40:1156-1168 • A thorough review of matrix metalloproteinase inhibitors as anticancer agents.
111. Elkin M, Reich R, Nagler A, et al. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 1999;5:1982-1988 (Pubitemid 29399247)
112. Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007;11:981-1011 (Pubitemid 350037046)
113. Chang CC, Shieh GS, Wu P, et al. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res 2008;68:6281-6291
114. Wu CL, Shieh GS, Chang CC, et al. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models. Clin Cancer Res 2008;14:1228-1238 (Pubitemid 351302572)
115. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522-528 (Pubitemid 46359633)
116. Font A, Taron M, Costa C, et al. BRCA1 mRNA expression in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy [abstract 5021]. J Clin Oncol 2008;26(May 20 Suppl)
117. Lorusso PM, Eder JP. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opin Investig Drugs 2008;17:1013-1028
118. Smolewski P. Investigating mammalian target of rapamycin inhibitors for their anticancer properties. Expert Opin Investig Drugs 2006;15:1201-1227 (Pubitemid 44608260)
119. Enokida H, Nakagawa M. Epigenetics in bladder cancer. Int J Clin Oncol 2008;13:298-307 •• An important review of epigenetic changes in urinary bladder cancer.
120. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006;94:776-780